MedTrace Logo

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

NCT05226507 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-08-08

No results posted yet for this study

Summary

The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.

Conditions

Interventions

DRUG

NXP800

NXP800 is an anti-neoplastic, oral small molecule.

Sponsors & Collaborators

  • Gynecologic Oncology Group Foundation

    collaborator UNKNOWN

  • The European Network for Gynaecological Oncological Trial groups (ENGOT)

    collaborator UNKNOWN

  • Nuvectis Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Udai Banerji, Prof · Institute of Cancer Research, Royal Marsden Foundation Trust

  • Susana Banerjee, Dr · Institute of Cancer Research, Royal Marsden NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-31
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05226507 on ClinicalTrials.gov